Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: ASE
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

Antisense Therapeutics Ltd

+ Add to Watchlist

ANP:AU

0.1200 AUD 0.0050 4.00%

As of 01:11:23 ET on 05/22/2015.

Snapshot for Antisense Therapeutics Ltd (ANP)

Open: 0.1250 Day's Range: 0.1200 - 0.1250 Volume: 228,487
Previous Close: 0.1250 52wk Range: 0.0800 - 0.1850 1-Yr Rtn: -11.11%

Stock Chart for ANP

No chart data available.
  • ANP:AU 0.1200
  • 1D
  • 1M
  • 1Y
0.1250
Interactive ANP Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for ANP

Current P/E Ratio (ttm) -
Estimated P/E(-) -
Relative P/E vs. AS51 -
Earnings Per Share (ttm) -0.0215
Est. EPS -
Est. PEG Ratio -
Market Cap (M AUD) 21.18
Shares Outstanding (M) 176.51
30 Day Average Volume 464,773
Price/Book (mrq) 8.4776
Price/Sale (ttm) -
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 08/25/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for ANP

  • Revenue
  • Net Income (M/AUD)
  • Profit Margin (%)

Company Profile & Key Executives for ANP

Antisense Therapeutics Limited develops and markets drugs for treatment of diseases like psoriasis, multiple sclerosis, autoimmune, cancer, metabolic and cardiovascular. The drugs are based on small synthetic genetic molecules. The Company has collaboration with Isis Pharmaceuticals in the United States, which provides the Company access to drug development technology.

Mark P DiamondCEO/Managing DirectorPhillip HainsCFO/Secretary
More Company Profile & Key Executives for ANP

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil